Mersana Therapeutics, Inc.
DelistedCIK 1442836fmd_1YX9DMEDQEM9DFDNR1CNBTHQXWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2025, 40 periods
Latest annual · FY2024
Millions- Total revenues
- 40
- Net income
- (69)
- Free cash flow
- (82)
Latest quarter · Q3 FY2025
Millions- Total revenues
- 11
- Net income
- (8)
- Free cash flow
- (3)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- +880.2%
- Revenue, 5 yearsFY2019 to FY2024
- -0.8%
- Net income, 5 yearsFY2019 to FY2024
- n/m
Mersana Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $40.5 million | $36.9 million | +9.9% | 10-K 2025-03-03 · proof |
| Net income | -$69.2 million | -$171.7 million | 10-K 2025-03-03 · proof | |
| Cash from operating activities | -$82.3 million | -$168.9 million | 10-K 2025-03-03 · proof | |
| Free cash flow | -$82.5 million | -$171.1 million | 10-K 2025-03-03 · proof | |
| Total assets | $144.7 million | $226.1 million | -36% | 10-K 2025-03-03 · proof |
| Total liabilities | $154.2 million | $189.2 million | -18.5% | 10-K 2025-03-03 · proof |
| Cash and cash equivalents | $107.8 million | $174.6 million | -38.3% | 10-K 2025-03-03 · proof |
| Total debt | $23.5 million | $25.2 million | -7.1% | 10-K 2025-03-03 · proof |
- What was Mersana Therapeutics, Inc.'s revenue in fiscal 2024?
- Mersana Therapeutics, Inc. reported revenue of $40.5 million for fiscal 2024 (the year ended Dec 31, 2024), against $36.9 million the year before (+9.9%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was Mersana Therapeutics, Inc.'s net income in fiscal 2024?
- Mersana Therapeutics, Inc. reported net income of -$69.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$171.7 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was Mersana Therapeutics, Inc.'s cash from operating activities in fiscal 2024?
- Mersana Therapeutics, Inc. reported cash from operating activities of -$82.3 million for fiscal 2024 (the year ended Dec 31, 2024), against -$168.9 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was Mersana Therapeutics, Inc.'s free cash flow in fiscal 2024?
- Mersana Therapeutics, Inc. reported free cash flow of -$82.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$171.1 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are Mersana Therapeutics, Inc.'s total assets?
- As of Dec 31, 2024, Mersana Therapeutics, Inc. reported total assets of $144.7 million, against $226.1 million a year earlier (-36%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are Mersana Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2024, Mersana Therapeutics, Inc. reported total liabilities of $154.2 million, against $189.2 million a year earlier (-18.5%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are Mersana Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Mersana Therapeutics, Inc. reported cash and cash equivalents of $107.8 million, against $174.6 million a year earlier (-38.3%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What is Mersana Therapeutics, Inc.'s total debt?
- As of Dec 31, 2024, Mersana Therapeutics, Inc. reported total debt of $23.5 million, against $25.2 million a year earlier (-7.1%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1442836&period_type=annual&limit=5"Information only, not investment advice.